Company intelligence / Profile preview
Exxel Pharma
Aurora, Colorado, United Statesexxelpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Exxel Pharma’s lead program, EX937, is a first-in-class oral small molecule FAAH inhibitor designed to treat refractory chronic cough by increasing anandamide levels and reducing neuronal hypersensitivity. Preclinical data show efficacy in models of cough, neuropathic pain, migraine, and hyperactive bladder with a favorable safety profile and peripheral action that avoids CNS side effects. The company is preparing for its first-in-human Phase 1/1b study in late 2025.
- Therapeutic areas
- PulmonologyPsychiatryNeurologyNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Exxel signed a sponsored research agreement with a large pharma company for its peripheral neuropathic pain therapeutic in November 2020terms for outlicensing the ARN program were finalized in March 2021
Beyond the preview
Go deeper on Exxel Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exxel Pharma.